JP7883446B2 - Her-2標的化二重特異性組成物ならびにその作製および使用のための方法 - Google Patents
Her-2標的化二重特異性組成物ならびにその作製および使用のための方法Info
- Publication number
- JP7883446B2 JP7883446B2 JP2022578997A JP2022578997A JP7883446B2 JP 7883446 B2 JP7883446 B2 JP 7883446B2 JP 2022578997 A JP2022578997 A JP 2022578997A JP 2022578997 A JP2022578997 A JP 2022578997A JP 7883446 B2 JP7883446 B2 JP 7883446B2
- Authority
- JP
- Japan
- Prior art keywords
- xten
- sequence
- amino acid
- antigen
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/101—Plasmid DNA for bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Dental Preparations (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Containers Having Bodies Formed In One Piece (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025145375A JP2026004299A (ja) | 2020-06-25 | 2025-09-02 | Her-2標的化二重特異性組成物ならびにその作製および使用のための方法 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063044301P | 2020-06-25 | 2020-06-25 | |
| US63/044,301 | 2020-06-25 | ||
| US202063077503P | 2020-09-11 | 2020-09-11 | |
| US63/077,503 | 2020-09-11 | ||
| US202063108783P | 2020-11-02 | 2020-11-02 | |
| US63/108,783 | 2020-11-02 | ||
| US202163166857P | 2021-03-26 | 2021-03-26 | |
| US63/166,857 | 2021-03-26 | ||
| US202163196408P | 2021-06-03 | 2021-06-03 | |
| US63/196,408 | 2021-06-03 | ||
| PCT/US2021/039006 WO2021263058A1 (en) | 2020-06-25 | 2021-06-24 | Her-2 targeted bispecific compositions and methods for making and using the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025145375A Division JP2026004299A (ja) | 2020-06-25 | 2025-09-02 | Her-2標的化二重特異性組成物ならびにその作製および使用のための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023531494A JP2023531494A (ja) | 2023-07-24 |
| JP2023531494A5 JP2023531494A5 (cg-RX-API-DMAC7.html) | 2024-09-25 |
| JP7883446B2 true JP7883446B2 (ja) | 2026-07-01 |
Family
ID=79281898
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022578997A Active JP7883446B2 (ja) | 2020-06-25 | 2021-06-24 | Her-2標的化二重特異性組成物ならびにその作製および使用のための方法 |
| JP2025145375A Pending JP2026004299A (ja) | 2020-06-25 | 2025-09-02 | Her-2標的化二重特異性組成物ならびにその作製および使用のための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025145375A Pending JP2026004299A (ja) | 2020-06-25 | 2025-09-02 | Her-2標的化二重特異性組成物ならびにその作製および使用のための方法 |
Country Status (12)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12022553407A1 (en) | 2020-06-25 | 2024-04-22 | Amunix Pharmaceuticals Inc | Her-2 targeted bispecific compositions and methods for making and using the same |
| JP7855148B2 (ja) | 2023-02-10 | 2026-05-07 | アムニクス ファーマシューティカルズ, インコーポレイテッド | 前立腺特異的膜抗原(psma)を標的とする組成物、並びにそれを作製及び使用するための方法 |
| US20240400696A1 (en) | 2023-04-17 | 2024-12-05 | Amunix Pharmaceuticals, Inc. | Compositions targeting epidermal growth factor receptor and methods for making and using the same |
| KR20260114559A (ko) | 2023-12-08 | 2026-07-22 | 아뮤닉스 파마슈티컬스, 인크. | 프로테아제 활성화가능 사이토카인 및 이의 제조 및 사용 방법 |
| GB2641580A (en) * | 2024-06-07 | 2025-12-10 | T Therapeutics Ltd | Tumour-transforming multispecific proteins |
| WO2026024863A2 (en) | 2024-07-24 | 2026-01-29 | Amunix Pharmaceuticals, Inc. | Compositions targeting prostate-specific membrane antigen (psma) in combination with androgen receptor antagonists |
| WO2026136923A1 (en) * | 2024-12-20 | 2026-06-25 | Vir Biotechnology, Inc. | Therapeutic uses of her-2 targeted bispecific polypeptides |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019126576A1 (en) | 2017-12-21 | 2019-06-27 | Amunix Pharmaceuticals, Inc. | Release segments and binding compositions comprising same |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3992518A (en) | 1974-10-24 | 1976-11-16 | G. D. Searle & Co. | Method for making a microsealed delivery device |
| GB1478759A (en) | 1974-11-18 | 1977-07-06 | Alza Corp | Process for forming outlet passageways in pills using a laser |
| US4284444A (en) | 1977-08-01 | 1981-08-18 | Herculite Protective Fabrics Corporation | Activated polymer materials and process for making same |
| US4200098A (en) | 1978-10-23 | 1980-04-29 | Alza Corporation | Osmotic system with distribution zone for dispensing beneficial agent |
| US4200984A (en) | 1979-03-12 | 1980-05-06 | Fink Ray D | Detachable tool combining bracket and method |
| US4398908A (en) | 1980-11-28 | 1983-08-16 | Siposs George G | Insulin delivery system |
| US4435173A (en) | 1982-03-05 | 1984-03-06 | Delta Medical Industries | Variable rate syringe pump for insulin delivery |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5916588A (en) | 1984-04-12 | 1999-06-29 | The Liposome Company, Inc. | Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use |
| US5231112A (en) | 1984-04-12 | 1993-07-27 | The Liposome Company, Inc. | Compositions containing tris salt of cholesterol hemisuccinate and antifungal |
| DE3581188D1 (de) | 1984-07-24 | 1991-02-07 | Key Pharma | Klebende schicht zur transdermalen freigabe. |
| US4684479A (en) | 1985-08-14 | 1987-08-04 | Arrigo Joseph S D | Surfactant mixtures, stable gas-in-liquid emulsions, and methods for the production of such emulsions from said mixtures |
| US6759057B1 (en) | 1986-06-12 | 2004-07-06 | The Liposome Company, Inc. | Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs |
| IE60901B1 (en) | 1986-08-21 | 1994-08-24 | Vestar Inc | Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics |
| US4933185A (en) | 1986-09-24 | 1990-06-12 | Massachusetts Institute Of Technology | System for controlled release of biologically active compounds |
| US6406713B1 (en) | 1987-03-05 | 2002-06-18 | The Liposome Company, Inc. | Methods of preparing low-toxicity drug-lipid complexes |
| US4976696A (en) | 1987-08-10 | 1990-12-11 | Becton, Dickinson And Company | Syringe pump and the like for delivering medication |
| US4861800A (en) | 1987-08-18 | 1989-08-29 | Buyske Donald A | Method for administering the drug deprenyl so as to minimize the danger of side effects |
| AU598958B2 (en) | 1987-11-12 | 1990-07-05 | Vestar, Inc. | Improved amphotericin b liposome preparation |
| GB8807504D0 (en) | 1988-03-29 | 1988-05-05 | Sandoz Ltd | Improvements in/relating to organic compounds |
| JP2717808B2 (ja) | 1988-08-10 | 1998-02-25 | テルモ株式会社 | シリンジポンプ |
| US5534617A (en) | 1988-10-28 | 1996-07-09 | Genentech, Inc. | Human growth hormone variants having greater affinity for human growth hormone receptor at site 1 |
| US5017378A (en) | 1989-05-01 | 1991-05-21 | The University Of Virginia Alumni Patents Foundation | Intraorgan injection of biologically active compounds contained in slow-release microcapsules or microspheres |
| US5298022A (en) | 1989-05-29 | 1994-03-29 | Amplifon Spa | Wearable artificial pancreas |
| US5492534A (en) | 1990-04-02 | 1996-02-20 | Pharmetrix Corporation | Controlled release portable pump |
| US5318540A (en) | 1990-04-02 | 1994-06-07 | Pharmetrix Corporation | Controlled release infusion device |
| US5176502A (en) | 1990-04-25 | 1993-01-05 | Becton, Dickinson And Company | Syringe pump and the like for delivering medication |
| US5215680A (en) | 1990-07-10 | 1993-06-01 | Cavitation-Control Technology, Inc. | Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles |
| US5206161A (en) | 1991-02-01 | 1993-04-27 | Genentech, Inc. | Human plasma carboxypeptidase B |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US5573776A (en) | 1992-12-02 | 1996-11-12 | Alza Corporation | Oral osmotic device with hydrogel driving member |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| US6491916B1 (en) | 1994-06-01 | 2002-12-10 | Tolerance Therapeutics, Inc. | Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies |
| US5660848A (en) | 1994-11-02 | 1997-08-26 | The Population Council, Center For Biomedical Research | Subdermally implantable device |
| ATE252372T1 (de) | 1996-08-23 | 2003-11-15 | Sequus Pharm Inc | Liposome enthaltend cisplatin |
| US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| WO1998016201A1 (en) | 1996-10-11 | 1998-04-23 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method |
| AU725257B2 (en) | 1996-10-15 | 2000-10-12 | Transave, Inc. | N-acyl phosphatidylethanolamine-mediated liposomal drug delivery |
| ATE314054T1 (de) | 1996-10-25 | 2006-01-15 | Shire Lab Inc | Osmotisches verabreichungssystem für lösliche dosen |
| US6361796B1 (en) | 1996-10-25 | 2002-03-26 | Shire Laboratories, Inc. | Soluble form osmotic dose delivery system |
| EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
| DE19747261A1 (de) | 1997-10-25 | 1999-04-29 | Bayer Ag | Osmotisches Arzneimittelfreisetzungssystem |
| ES2255155T3 (es) | 1998-02-05 | 2006-06-16 | Biosense Webster, Inc. | Dispositivo para la administracion intracardiaca de farmacos. |
| US6406632B1 (en) | 1998-04-03 | 2002-06-18 | Symyx Technologies, Inc. | Rapid characterization of polymers |
| GB9815157D0 (en) | 1998-07-13 | 1998-09-09 | Metron Designs Ltd | High resolution pulse width setting from relatively low frequency clocks |
| US6713086B2 (en) | 1998-12-18 | 2004-03-30 | Abbott Laboratories | Controlled release formulation of divalproex sodium |
| NZ514442A (en) | 1999-03-03 | 2003-08-29 | Optinose As | Nasal delivery device |
| US6183770B1 (en) | 1999-04-15 | 2001-02-06 | Acutek International | Carrier patch for the delivery of agents to the skin |
| US6743211B1 (en) | 1999-11-23 | 2004-06-01 | Georgia Tech Research Corporation | Devices and methods for enhanced microneedle penetration of biological barriers |
| US6352721B1 (en) | 2000-01-14 | 2002-03-05 | Osmotica Corp. | Combined diffusion/osmotic pumping drug delivery system |
| US20030228309A1 (en) | 2000-11-08 | 2003-12-11 | Theodora Salcedo | Antibodies that immunospecifically bind to TRAIL receptors |
| IN190699B (cg-RX-API-DMAC7.html) | 2001-02-02 | 2003-08-16 | Sun Pharmaceutical Ind Ltd | |
| US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
| CA2445860A1 (en) | 2001-04-30 | 2002-11-07 | Shire Laboratories Inc. | Pharmaceutical composition including ace/nep inhibitors and bioavailability enhancers |
| US6838093B2 (en) | 2001-06-01 | 2005-01-04 | Shire Laboratories, Inc. | System for osmotic delivery of pharmaceutically active agents |
| KR100407467B1 (ko) | 2001-07-12 | 2003-11-28 | 최수봉 | 리모컨 방식의 인슐린 자동주사기 |
| US6945952B2 (en) | 2002-06-25 | 2005-09-20 | Theraject, Inc. | Solid solution perforator for drug delivery and other applications |
| US7294513B2 (en) | 2002-07-24 | 2007-11-13 | Wyatt Technology Corporation | Method and apparatus for characterizing solutions of small particles |
| SG188175A1 (en) | 2004-06-03 | 2013-03-28 | Novimmune Sa | Anti-cd3 antibodies and methods of use thereof |
| AU2006291005A1 (en) | 2005-09-12 | 2007-03-22 | Novimmune S.A. | Anti-CD3 antibody formulations |
| KR101837053B1 (ko) | 2008-10-01 | 2018-03-12 | 암젠 리서치 (뮌헨) 게엠베하 | 종간 특이적 PSCAxCD3, CD19xCD3, c-METxCD3, 엔도시알린xCD3, EpCAMxCD3, IGF-1RxCD3 또는 FAPαxCD3 이중특이적 단일쇄 항체 |
| US8680050B2 (en) | 2009-02-03 | 2014-03-25 | Amunix Operating Inc. | Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same |
| DK3178835T3 (da) | 2009-02-03 | 2019-06-24 | Amunix Pharmaceuticals Inc | Forlængede rekombinante polypeptider og sammensætninger omfattende samme |
| US8703717B2 (en) | 2009-02-03 | 2014-04-22 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
| WO2010144508A1 (en) | 2009-06-08 | 2010-12-16 | Amunix Operating Inc. | Glucose-regulating polypeptides and methods of making and using same |
| PE20121539A1 (es) | 2009-06-08 | 2012-12-06 | Amunix Operating Inc | Polipeptidos de la hormona de crecimiento y metodos de preparacion |
| CA2771999A1 (en) | 2009-08-24 | 2011-03-10 | Amunix Operating Inc. | Coagulation factor vii compositions and methods of making and using same |
| WO2011028344A2 (en) | 2009-08-25 | 2011-03-10 | Amunix Operating Inc. | Interleukin-1 receptor antagonist compositions and methods of making and using same |
| WO2011123830A2 (en) | 2010-04-02 | 2011-10-06 | Amunix Operating Inc. | Alpha 1-antitrypsin compositions and methods of making and using same |
| EP4450523A3 (en) | 2010-04-02 | 2025-03-12 | Amunix Pharmaceuticals, Inc. | Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same |
| ES2770501T3 (es) | 2012-07-11 | 2020-07-01 | Bioverativ Therapeutics Inc | Complejo del factor VIII con XTEN y proteína del factor de Von Willebrand y sus usos |
| US10548953B2 (en) | 2013-08-14 | 2020-02-04 | Bioverativ Therapeutics Inc. | Factor VIII-XTEN fusions and uses thereof |
| WO2016077505A2 (en) * | 2014-11-11 | 2016-05-19 | Amunix Operating Inc. | Targeted xten conjugate compositions and methods of making same |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| CN111787949A (zh) * | 2018-02-15 | 2020-10-16 | 宏观基因有限公司 | 变体cd3-结合结构域及其在用于治疗疾病的组合疗法中的用途 |
| WO2020264200A1 (en) | 2019-06-26 | 2020-12-30 | Amunix Pharmceuticals, Inc. | Cd3 antigen binding fragments and compositions comprising same |
| US20230312729A1 (en) | 2019-06-26 | 2023-10-05 | Amunix Pharmaceuticals, Inc. | Egfr antigen binding fragments and compositions comprising same |
| EP4058466A1 (en) | 2019-11-13 | 2022-09-21 | Amunix Pharmaceuticals, Inc. | Barcoded xten polypeptides and compositions thereof, and methods for making and using the same |
| PH12022553407A1 (en) | 2020-06-25 | 2024-04-22 | Amunix Pharmaceuticals Inc | Her-2 targeted bispecific compositions and methods for making and using the same |
-
2021
- 2021-06-24 PH PH1/2022/553407A patent/PH12022553407A1/en unknown
- 2021-06-24 MX MX2022016387A patent/MX2022016387A/es unknown
- 2021-06-24 EP EP21829062.5A patent/EP4172179A4/en active Pending
- 2021-06-24 CA CA3182372A patent/CA3182372A1/en active Pending
- 2021-06-24 KR KR1020237002752A patent/KR20230041711A/ko active Pending
- 2021-06-24 WO PCT/US2021/039006 patent/WO2021263058A1/en not_active Ceased
- 2021-06-24 JP JP2022578997A patent/JP7883446B2/ja active Active
- 2021-06-24 IL IL298815A patent/IL298815A/en unknown
- 2021-06-24 AU AU2021297984A patent/AU2021297984C1/en active Active
- 2021-06-24 BR BR112022026420A patent/BR112022026420A2/pt unknown
-
2022
- 2022-12-10 US US18/064,253 patent/US20230322922A1/en active Pending
-
2023
- 2023-01-11 CO CONC2023/0000247A patent/CO2023000247A2/es unknown
- 2023-10-25 US US18/494,007 patent/US12215156B2/en active Active
-
2025
- 2025-09-02 JP JP2025145375A patent/JP2026004299A/ja active Pending
- 2025-12-10 AU AU2025279644A patent/AU2025279644A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019126576A1 (en) | 2017-12-21 | 2019-06-27 | Amunix Pharmaceuticals, Inc. | Release segments and binding compositions comprising same |
Non-Patent Citations (2)
| Title |
|---|
| Advanced Drug Delivery Reviews,2013年,65,pp.1357-1369 |
| 薬剤学,2012年,72(5),pp.276-282 |
Also Published As
| Publication number | Publication date |
|---|---|
| PH12022553407A1 (en) | 2024-04-22 |
| EP4172179A1 (en) | 2023-05-03 |
| BR112022026420A2 (pt) | 2023-04-18 |
| AU2021297984A1 (en) | 2023-02-23 |
| EP4172179A4 (en) | 2024-11-20 |
| AU2021297984C1 (en) | 2025-12-11 |
| WO2021263058A1 (en) | 2021-12-30 |
| IL298815A (en) | 2023-02-01 |
| CA3182372A1 (en) | 2021-12-30 |
| US12215156B2 (en) | 2025-02-04 |
| MX2022016387A (es) | 2023-04-11 |
| AU2025279644A1 (en) | 2026-01-15 |
| JP2026004299A (ja) | 2026-01-14 |
| US20240076378A1 (en) | 2024-03-07 |
| AU2021297984B2 (en) | 2025-09-11 |
| US20230322922A1 (en) | 2023-10-12 |
| KR20230041711A (ko) | 2023-03-24 |
| CO2023000247A2 (es) | 2023-01-26 |
| JP2023531494A (ja) | 2023-07-24 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20240422 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20240513 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240624 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240624 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240912 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20241101 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20241111 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250603 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250902 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20251014 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260107 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260313 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260526 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260619 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7883446 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |